Precise execution

MC Services is...

Client News



… an international Corporate Communications and Investor Relations firm providing high-level consultancy with targeted services and support for transaction-oriented assignments throughout Europe and the United States.


read more


MC Services AG is looking forward to BIO-Europe 2016 in Cologne


Organized by the EBD Group, the 22nd BIO-Europe, the international partnering conference, this year will take place in Cologne, Germany from November 7 to 9, 2016. Serving the global life science industry, BIO-Europe offers various opportunities for high quality networking by attracting a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts. As media partner, MC Services invites local and international journalist to the event and keeps them informed on the presenting company executives and attending investors. Additional Information on MC Services’ engagement and activities during the conference will be announced soon.


Please follow us on Twitter (@MCServicesAG)

Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100


ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on “HIV Drug Therapy” in Glasgow, Scotland


SYGNIS AG to receive €1.9 million non-dilutive R&D funding from the Spanish government


MagForce AG participates in four upcoming international conferences in Q4 2016


CEVEC submits Biologics Master File (BB-MF) for CAP(R) Technology to the U.S. FDA 


Verona Pharma receives second Venture and Innovation Award from Cystic Fibrosis Trust


Epigenomics AG: Journal of the American Medical Association (JAMA) publishes “letter to the editor” that clarifies clinical performance data for Epi proColon®


VAXIMM Announces Presentations at Upcoming Industry and Scientific Events 


Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug 


Xenikos to participate in BIO-Europe(R) 2016 - 22nd Annual International Partnering Conference


Ergomed notes co-development partner Dilaforette's intention to conduct an Initial Public Offering and change of name to Modus Therapeutics


US FDA considers Newron’s re-submitted NDA for Xadago® to be a complete, class 2 response to Complete Response Letter PDUFA date March 21, 2017


RedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB-104 for Multiple Sclerosis


MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody


Transgene Reports Third Quarter 2016 Financial Results